{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:23:25Z","timestamp":1790508205113,"version":"4.1.0"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Latin Link Nederland"},{"name":"Fundaci\u00f3n Quina Care Ecuador"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Cutaneous and mucocutaneous leishmaniasis affect a million people yearly, leading to skin lesions and potentially disfiguring mucosal disease. Current treatments can have severe side effects. Allylamine drugs, like terbinafine, are safe, including during pregnancy. This review assesses efficacy and safety of allylamines for the treatment of cutaneous and mucocutaneous leishmaniasis. It followed the PRISMA statement for reporting and was preregistered in PROSPERO(CRD4201809068). MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Global Health Library, Web of Science, Google Scholar, and clinical trial registers were searched from their creation to May 24\n                    <jats:sup>th<\/jats:sup>\n                    , 2020. All original human, animal, and\n                    <jats:italic>in vitro<\/jats:italic>\n                    studies concerning allylamines and cutaneous or mucocutaneous leishmaniasis were eligible for inclusion. Comparators\u2014if any\u2014included both placebo or alternative cutaneous or mucocutaneous leishmaniasis treatments. Complete cure, growth inhibition, or adverse events served as outcomes. The search identified 312 publications, of which 22 were included in this systematic review. There were one uncontrolled and two randomised controlled trials. The only well-designed randomised controlled trial that compared the treatment efficacy of oral terbinafine versus intramuscular meglumine antimoniate in 80\n                    <jats:italic>Leismania tropica<\/jats:italic>\n                    infected patients showed a non-significant lower cure rate for terbinafine vs meglumine antimoniate (38% vs 53%). A meta-analysis could not be performed due to the small number of studies, their heterogeneity, and low quality. This systematic review shows that there is no evidence of efficacy of allylamine monotherapy against cutaneous and mucocutaneous leishmaniasis. Further trials of allylamines should be carefully considered as the outcomes of an adequately designed trial were disappointing and\n                    <jats:italic>in vitro<\/jats:italic>\n                    studies indicate minimal effective concentrations that are not achieved in the skin during standard doses. However, the\n                    <jats:italic>in vitro<\/jats:italic>\n                    synergistic effects of allylamines combined with triazole drugs warrant further exploration.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0249628","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T16:04:40Z","timestamp":1617811480000},"page":"e0249628","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety and efficacy of allylamines in the treatment of cutaneous and mucocutaneous leishmaniasis: A systematic review"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-1341","authenticated-orcid":true,"given":"Jacob M.","family":"Bezemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Limpens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J. C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk D. F. H.","family":"Schallig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"5","key":"pone.0249628.ref001","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"J Alvar","year":"2012","journal-title":"PLoS ONE"},{"issue":"10066","key":"pone.0249628.ref002","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(16)30171-4","article-title":"Neglected tropical diseases: progress towards addressing the chronic pandemic","volume":"389","author":"DH Molyneux","year":"2017","journal-title":"Lancet (London, England)."},{"issue":"3","key":"pone.0249628.ref003","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4269\/ajtmh.16-0349","article-title":"Mucosal leishmaniasis: A retrospective study of 327 cases from an endemic area of Leishmania (Viannia) braziliensis","volume":"97","author":"C Cincura","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"5","key":"pone.0249628.ref004","doi-asserted-by":"crossref","first-page":"e2832","DOI":"10.1371\/journal.pntd.0002832","article-title":"Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide","volume":"8","author":"CJ Hodiamont","year":"2014","journal-title":"PLoS neglected tropical diseases"},{"key":"pone.0249628.ref005","first-page":"Cd004834","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"M Pinart","year":"2020","journal-title":"The Cochrane database of systematic reviews"},{"issue":"12","key":"pone.0249628.ref006","first-page":"Cd005067","article-title":"Interventions for Old World cutaneous leishmaniasis","volume":"12","author":"J Heras-Mosteiro","year":"2017","journal-title":"The Cochrane database of systematic reviews"},{"issue":"3","key":"pone.0249628.ref007","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most","volume":"3","author":"T Sunyoto","year":"2018","journal-title":"BMJ global health"},{"issue":"2","key":"pone.0249628.ref008","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World","volume":"118","author":"LF Oliveira","year":"2011","journal-title":"Acta tropica"},{"key":"pone.0249628.ref009","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.reprotox.2014.10.016","article-title":"Effects of in utero and lactational exposure to SbV on rat neurobehavioral development and fertility","volume":"50","author":"DR Coelho","year":"2014","journal-title":"Reproductive toxicology (Elmsford, NY)."},{"issue":"2","key":"pone.0249628.ref010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40257-015-0114-z","article-title":"Cutaneous leishmaniasis: recent developments in diagnosis and management.","volume":"16","author":"HJ de Vries","year":"2015","journal-title":"American journal of clinical dermatology"},{"issue":"20","key":"pone.0249628.ref011","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1016\/0006-2952(85)90250-3","article-title":"Effect of the allylamine antifungal drug SF 86\u2013327 on the growth and sterol synthesis of Leishmania mexicana mexicana promastigotes","volume":"34","author":"LJ Goad","year":"1985","journal-title":"Biochem Pharmacol"},{"issue":"4654","key":"pone.0249628.ref012","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1126\/science.6547247","article-title":"Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase","volume":"224","author":"G Petranyi","year":"1984","journal-title":"Science"},{"key":"pone.0249628.ref013","first-page":"Cd010031","article-title":"Oral antifungal medication for toenail onychomycosis","volume":"7","author":"S Kreijkamp-Kaspers","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"pone.0249628.ref014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4103\/idoj.IDOJ_169_17","article-title":"Treatment of Dermatophytosis in Elderly, Children, and Pregnant Women.","volume":"8","author":"S Kaul","year":"2017","journal-title":"Indian dermatology online journal"},{"key":"pone.0249628.ref015","author":"Terbinafine","year":"2006"},{"issue":"7","key":"pone.0249628.ref016","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS medicine"},{"issue":"10Suppl 1","key":"pone.0249628.ref017","article-title":"A revised tool for assessing risk of bias in randomized trials","author":"SJ Higgins JPT","year":"2016","journal-title":"Cochrane Methods Cochrane Database of Systematic Reviews"},{"issue":"4919","key":"pone.0249628.ref018","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions.","volume":"355","author":"JAC Sterne","year":"2016","journal-title":"british journal of medicine"},{"key":"pone.0249628.ref019","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies.","volume":"14","author":"CR Hooijmans","year":"2014","journal-title":"BMC medical research methodology"},{"key":"pone.0249628.ref020","author":"OHAT","year":"2015"},{"issue":"Suppl 2","key":"pone.0249628.ref021","first-page":"s242","article-title":"In vitro and in vivo effect of terbinafine in cutaneous leishmaniasis","volume":"11","author":"\u00dc Uk\u015fal","year":"1998","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"pone.0249628.ref022","first-page":"128","article-title":"Estudo da efic\u00e1cia da terbinafina, in vitro. Resumos do IV Congresso de Inicia\u00e7\u00e3o Cient\u00edfica da Universidade de Bras\u00edlia","author":"AF Bonatto","year":"1998"},{"issue":"11","key":"pone.0249628.ref023","first-page":"811","article-title":"A case of cutaneous leishmaniasis misdiagnosed as cutaneous aspergillosis and successfully treated with terbinafine","volume":"44","author":"GAO Lu-juan","year":"2011","journal-title":"Chinese Journal of Dermatology"},{"issue":"118","key":"pone.0249628.ref024","first-page":"1246","article-title":"Comparetaive Study on Glucantime and Oral Terbinafine along with Systemic Glucantime on Cutaneous Leishmaniasis","volume":"28","author":"S Ebrahimian","year":"2011","journal-title":"J Isfahan Med Sch"},{"issue":"1","key":"pone.0249628.ref025","first-page":"1","article-title":"Comparison between Combination Therapy of Oral Terbinafine and Cryotherapy versus Systemic Meglumine Antimoniate and Cryotherapy in Cutaneous Leishmaniasis: A Randomized Clinical Trial.","volume":"10","author":"S Farajzadeh","year":"2015","journal-title":"Iranian J Parasitol"},{"issue":"4","key":"pone.0249628.ref026","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s12639-014-0641-1","article-title":"Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial","volume":"40","author":"S Farajzadeh","year":"2016","journal-title":"J Parasit Dis"},{"issue":"1","key":"pone.0249628.ref027","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-4362.1997.00021.x","article-title":"Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study","volume":"36","author":"KA Bahamdan","year":"1997","journal-title":"Int J Dermatol"},{"issue":"8","key":"pone.0249628.ref028","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/00034983.2000.11813603","article-title":"Effects of itraconazole and terbinafine on Leishmania major lesions in BALB\/c mice","volume":"94","author":"HA Zakai","year":"2000","journal-title":"Ann Trop Med Parasitol"},{"issue":"4","key":"pone.0249628.ref029","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1590\/S0037-86822003000400018","article-title":"In vivo Terbinafine inefficacy on cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis in C57BL\/6 mice","volume":"36","author":"RN Sampaio","year":"2003","journal-title":"Rev Soc Bras Med Trop"},{"key":"pone.0249628.ref030","author":"VV Andrade-Neto","year":"2013"},{"issue":"2\u20133","key":"pone.0249628.ref031","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.actatropica.2011.05.001","article-title":"The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis","volume":"119","author":"VV Andrade-Neto","year":"2011","journal-title":"Acta Trop"},{"key":"pone.0249628.ref032","author":"VV Andrade-Neto","year":"2009"},{"key":"pone.0249628.ref033","volume-title":"Leishmaniasis","author":"DH Beach","year":"1989"},{"issue":"3","key":"pone.0249628.ref034","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2307\/3282158","article-title":"In vitro antileishmanial activity of inhibitors of steroid biosynthesis and combinations of antileishmanial agents","volume":"73","author":"JD Berman","year":"1987","journal-title":"J Parasitol"},{"issue":"6","key":"pone.0249628.ref035","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.parint.2016.08.003","article-title":"The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis","volume":"65","author":"A Bezerra-Souza","year":"2016","journal-title":"Parasitol Int"},{"issue":"2","key":"pone.0249628.ref036","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/00034983.1999.11813410","article-title":"Observations on leucine incorporation into sterol by Leishmania, and its inhibition by terbinafine","volume":"93","author":"ML Chance","year":"1999","journal-title":"Ann Trop Med Parasitol"},{"issue":"12","key":"pone.0249628.ref037","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1128\/AAC.40.12.2785","article-title":"Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes","volume":"40","author":"H Rangel","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0249628.ref038","first-page":"9","article-title":"Comparative study on susceptibility of Leishmania isolated from dermal leishmaniasis to antifungal drug terbinafine and classic antileishmanial drugs","volume":"11","author":"P Tariq","year":"1994","journal-title":"Pakistan Journal of Pharmacology"},{"issue":"4","key":"pone.0249628.ref039","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1550-7408.1995.tb01591.x","article-title":"Alterations induced by the antifungal compounds ketoconazole and terbinafine in Leishmania","volume":"42","author":"MA Vannier-Santos","year":"1995","journal-title":"J Eukaryot Microbiol"},{"issue":"1","key":"pone.0249628.ref040","first-page":"97","article-title":"Effect of itraconazole and terbinafine on Leishmania promastigotes","volume":"33","author":"HA Zakai","year":"2003","journal-title":"J Egypt Soc Parasitol"},{"issue":"1","key":"pone.0249628.ref041","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tmaid.2004.11.002","article-title":"Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis","volume":"4","author":"JJ Scarisbrick","year":"2006","journal-title":"Travel Medicine and Infectious Disease"},{"key":"pone.0249628.ref042","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-4362.1996.tb01651.x","article-title":"Cutaneous leishmaniasis in the north of Italy","volume":"35","author":"G Albanese","year":"1996","journal-title":"Int J Dermatol"},{"issue":"1","key":"pone.0249628.ref043","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000246067","article-title":"Remission of localized cutaneous leishmaniasis in a HIV-positive patient using systemic terbinafine","volume":"194","author":"J Gonzalez-Ruperez","year":"1997","journal-title":"Dermatology"},{"issue":"3","key":"pone.0249628.ref044","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20183172","article-title":"A case of cutaneous leishmaniasis successfully treated with oral terbinafine in Kenya.","volume":"4","author":"RL Mawenzi","year":"2018","journal-title":"International Journal of Research in Dermatology"},{"issue":"2","key":"pone.0249628.ref045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0003-438X(05)82333-3","article-title":"Leishmaniose nasale","volume":"122","author":"JF Vellin","year":"2005","journal-title":"Annales d\u2019Otolaryngologie et de Chirurgie Cervico-faciale"},{"issue":"4","key":"pone.0249628.ref046","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/000155557300304","article-title":"Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks","volume":"73","author":"J Faergemann","year":"1993","journal-title":"Acta dermato-venereologica"},{"issue":"2","key":"pone.0249628.ref047","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2230.1989.tb00904.x","article-title":"Clinical pharmacokinetics of terbinafine (Lamisil).","volume":"14","author":"JC Jensen","year":"1989","journal-title":"Clinical and experimental dermatology"},{"issue":"5","key":"pone.0249628.ref048","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2133.1995.tb00711.x","article-title":"Overview of the use of terbinafine (Lamisil) in children","volume":"132","author":"TC Jones","year":"1995","journal-title":"The British journal of dermatology"},{"issue":"5","key":"pone.0249628.ref049","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0190-9622(98)70483-9","article-title":"Pharmacokinetics and pharmacology of terbinafine and itraconazole","volume":"38","author":"J Leyden","year":"1998","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"pone.0249628.ref050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/AAC.00751-13","article-title":"Simple colorimetric trypanothione reductase-based assay for high-throughput screening of drugs against Leishmania intracellular amastigotes","volume":"58","author":"E van den Bogaart","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0249628.ref051","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1371\/journal.pntd.0001253","article-title":"A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"G De Muylder","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pone.0249628.ref052","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7547\/13-110.1","article-title":"Therapies for onychomycosis a systematic review and network meta-analysis of mycological cure","volume":"105","author":"AK Gupta","year":"2015","journal-title":"Journal of the American Podiatric Medical Association"},{"issue":"4","key":"pone.0249628.ref053","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/17425255.2018.1461834","article-title":"Common drug-drug interactions in antifungal treatments for superficial fungal infections","volume":"14","author":"AK Gupta","year":"2018","journal-title":"Expert opinion on drug metabolism & toxicology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0249628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T16:46:38Z","timestamp":1724777198000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0249628"}},"subtitle":[],"editor":[{"given":"Kristien","family":"Verdonck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0249628","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]}}}